Q2050 HCPCS code: Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Q2050 is the HCPCS Level II code for injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg. In 2024 Medicare paid an average of $90.44 per service for Q2050 across 33,348 services. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 20 per day on outpatient hospital claims. Medicare volume fell 25% from 2022 to 2024 (44,651 to 33,348 services). In 2024, about 1,545 clinicians billed Medicare for Q2050 for 1,529 beneficiaries; California, Texas, Florida accounted for 37% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2013-07-01 |
| Last action effective | 2013-07-01 |
Who bills Q2050 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,545 |
| Medicare beneficiaries | 1,529 |
| States with claims | 32 |
| Share of services in top 3 states (California, Texas, Florida) | 37% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q2050, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 44,651 | 1,968 | $154.63 | $123.36 |
| 2023 | 37,268 | 1,660 | $99.84 | $79.41 |
| 2024 | 33,348 | 1,529 | $113.75 | $90.44 |
States with the most Q2050 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 4,442 | $90.47 |
| Texas | 4,203 | $90.06 |
| Florida | 3,308 | $91.52 |
| Virginia | 1,576 | $90.71 |
| Maryland | 1,533 | $91.10 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 20 | Clinical: CMS Workgroup |
| practitioner claims | 14 | Clinical: CMS Workgroup |
What changed for Q2050
- 2013-07-01: Q2050 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q2050?
Q2050 is the HCPCS Level II code for injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg. Short descriptor: "Doxorubicin inj 10mg".
How much does Medicare pay for Q2050?
In 2024, the average Medicare payment was $90.44 per service (average allowed $113.75).
Does Medicare cover Q2050?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
How many units of Q2050 can be billed per day?
20 on outpatient hospital claims; 14 on practitioner claims (NCCI medically unlikely edits).
Related Q20 codes
- Q2004 — Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
- Q2009 — Injection, fosphenytoin, 50 mg phenytoin equivalent
- Q2017 — Injection, teniposide, 50 mg
- Q2026 — Injection, radiesse, 0.1 ml
- Q2028 — Injection, sculptra, 0.5 mg
- Q2034 — Influenza virus vaccine, split virus, for intramuscular use (agriflu)
- Q2035 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
- Q2036 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
- Q2037 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
- Q2038 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
- Q2039 — Influenza virus vaccine, not otherwise specified
- Q2040 — Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q2050
- Watch Q2050 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q2050
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.